Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Blood (2023) 142 (Supplement 1): 4641.

https://doi.org/10.1182/blood-2023-181595

Published: 2023

Journal Articles

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Blood (2022) 140 (Supplement 1): 6279–6281.

https://doi.org/10.1182/blood-2022-169696

Published: 2022

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Characterisation of a New Clinical Presentation of Chronic Lymphocytic Leukemia with Symptomatic Nasopharyngeal Mucosa Involvement

Thimali Ranaweera Arachchige, Antoine Diep, Ambroise David, Melchior Le Mene, Virginie Eclache, Rémi Letestu, Xavier Troussard, Antoine Martin, Catherine Mendiburu, Fanny Baran-Marszak, Florence Cymbalista, Gregory Lazarian

Blood (2021) 138 (Supplement 1): 3741.

https://doi.org/10.1182/blood-2021-144958

Published: 2021

Journal Articles

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Blood (2021) 138 (Supplement 1): 637.

https://doi.org/10.1182/blood-2021-152515

Published: 2021

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Blood (2019) 134 (Supplement_1): 3038.

https://doi.org/10.1182/blood-2019-126720

Published: 2019

Journal Articles

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

Anne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, Loïc Ysebaert, Carole Fleury, Grégory Lazarian, Marie-Sarah Dilhuydy, Delphine Nollet, Romain Guieze, Pierre Feugier, Damien Roos-Weil, Lise Willems, Anne-Sophie Michallet, Alain Delmer, Katia Hormigos, Vincent Levy, Florence Cymbalista, Fanny Baran-Marszak

Blood (2019) 134 (7): 641–644.

https://doi.org/10.1182/blood.2019000854

Published: 2019

Includes: Supplemental data

Journal Articles

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

Anne Quinquenel, Luc Matthieu Fornecker, Remi Letestu, Carole Fleury, Loic Ysebaert, MD PhD, Marie-Sarah Dilhuydy, MD, Romain Guieze, MD, Pierre Feugier, Damien Roos-Weil, MD, Lise Willems, MD, Anne-Sophie Michallet, MD PhD, Alain Jacques Delmer, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Vincent Levy, MD PhD, Florence Cymbalista, MD, Fanny Baran-Marszak, MD PhD

Blood (2018) 132 (Supplement 1): 584.

https://doi.org/10.1182/blood-2018-99-114027

Published: 2018

Journal Articles

High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial

Blood (2018) 132 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2018-99-111977

Published: 2018

Journal Articles

First Interim Analysis of the French National Observatory of Paroxysmal Nocturnal Hemoglobinuria Clones

Magali Le Garff-Tavernier, Bernard Drenou, MD, Agathe Pruvot Debliquis, Remi Letestu, Bernard Chatelain, PhD BPharm, Thomas Boyer, Jean-Philippe Vial, MD, Michael Peres, MD, Véronique Harrivel, MD, Gérard Socié, MDPhD, Regis Peffault De Latour, MD PhD, Orianne Wagner Ballon

Blood (2017) 130 (Supplement 1): 4960.

https://doi.org/10.1182/blood.V130.Suppl_1.4960.4960

Published: 2017

Journal Articles

Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study

Blood (2017) 130 (Supplement 1): 497.

https://doi.org/10.1182/blood.V130.Suppl_1.497.497

Published: 2017

Journal Articles

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Blood (2017) 130 (Supplement 1): 1722.

https://doi.org/10.1182/blood.V130.Suppl_1.1722.1722

Published: 2017

Journal Articles

Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

David Gottlieb, MBBS MDFRACP FRCPA, Thérèse Aurran, MD, Constantine S. Tam, MD, Mary Sartor, PhD, Rémi Letestu, MD PhD, Dennis Carney, Gavin Cull, MBBS DM FRACP FRCPA, Vincent Levy, MD PhD, Veronique Leblond, MD PhD, Marie Christine Bene, Andrew Budniak, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Florence Cymbalista, MD PhD

Blood (2016) 128 (22): 2053.

https://doi.org/10.1182/blood.V128.22.2053.2053

Published: 2016

Journal Articles

Splicing Factor 3B Subunit 1 (SF3B1) Mutations Impact FOXP1 Splicing in Chronic Lymphocytic Leukemia (CLL) Cells but Conserve the Balance Between Newly Described and Classical Splicing Variants of ZAP-70

Herve Roudot, MD, Jennifer Martret, Fanny Baran-Marszak, Jean-Francois Collon, Abdemalek Dahmani, Valerie Lefebvre, Xavier Troussard, MD PhD, Florence Cymbalista, MD PhD, Nadine Varin-Blank, PhD, Remi Letestu, MD PhD

Blood (2015) 126 (23): 2927.

https://doi.org/10.1182/blood.V126.23.2927.2927

Published: 2015

Journal Articles

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Andy Rawstron, PhD, Claudia Fazi, PhD, Neus Villamor, MD PhD, Julio Delgado, MD PhD, Remi Letestu, MD PhD, Florence Cymbalista, MD, Carlos Palacio, Francesc Bosch, MD PhD, Ruth M De Tute, MSc, Stuart Liptrot, David O'Brien, FAMLs, Martin Spacek, MD, PhD, Johan Dobber, Arnon P. Kater, MD PhD, Peter C Gambell, David A Westerman, MBBS, FRACP, FRCPA, Asha Soosapilla, Stephen P. Mulligan, MBBS, PhD FRACP, FRCPA, Gerard Lozanski, MD, Ke Lin, PhD, Andrew R Pettitt, MRCP, PhD, Gabi Brachtl, Alexander Egle, MD, David W Williamson, PhD, Catherine M Sanders, PhD, Harlan Robins, PhD, Justin Boysen, Tait D. Shanafelt, MD, Curtis A. Hanson, MD, Jeffrey L. Jorgensen, MD PhD, William G. Wierda, MD PhD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Laura Rassenti, PhD, H. Elizabeth Broome, MD, Thomas J. Kipps, MD PhD, Mathieu Hauwel, Iuri Marinov, Fiona E. Craig, MBBS, Nomdedeu Josep, Carol Moreno, MD, Olga Stehlikova, MSc., Michael Doubek, Sarka Pospisilova, Prof., Dr., PhD, Karl-Anton Kreuzer, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Emili Montserrat, MD PhD, Paolo Ghia, MD

Blood (2014) 124 (21): 1976.

https://doi.org/10.1182/blood.V124.21.1976.1976

Published: 2014

NARROW

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Characterisation of a New Clinical Presentation of Chronic Lymphocytic Leukemia with Symptomatic Nasopharyngeal Mucosa Involvement

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial

First Interim Analysis of the French National Observatory of Paroxysmal Nocturnal Hemoglobinuria Clones

Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Splicing Factor 3B Subunit 1 (SF3B1) Mutations Impact FOXP1 Splicing in Chronic Lymphocytic Leukemia (CLL) Cells but Conserve the Balance Between Newly Described and Classical Splicing Variants of ZAP-70

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only